🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Dr. Lal PathLabs Limited LALPATHLAB NIFTY_SMALLNSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.lalpathlabs.com
Company Profile ↓
₹1,843.70
+14.37% 1Y
Mkt Cap₹30,828.64 Cr
P/E56.90
P/B12.87
Div. Yield1.05%
52W High₹2,005.10
52W Low₹1,300.98
Book Value₹150.21
EPS (TTM)₹32.40

Company Overview

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 25.7%.

Consistent Profit Growth

Net profit has compounded at 28.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.1% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 18.7%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.08.

Recent Developments

  • Mar 2026 Revenue of ₹2,762.76 Cr (+12.3% YoY); net profit ₹504.78 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.1%, earnings +27.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.1%, profit CAGR 28.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.06%
1 Year:19.10%

Compounded Profit Growth

5 Years:28.33%
1 Year:27.80%

Stock Price Performance

1 Year:+14.37%
6 Months:+30.87%
3 Months:+9.57%
1 Month:-3.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 77% of range
₹1,300.98 ₹2,005.10
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)39.56 · Neutral
Price Performance
1M-3.99%
3M+9.57%
6M+30.87%
1Y+14.37%
Valuation vs Sector

P/E of 56.90 is above the sector median of 35.90 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.1%.
  • Healthy ROCE of 25.7%.
  • Compounding revenue at 11.1% over 5 years.
  • Profit CAGR of 28.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 56.9.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
56.90
Industry PE
35.90
Forward P/E
42.11
PEG Ratio
-
Book Value
₹150.21
Price to Book
12.87
P/S
11.18
EV/EBITDA
38.75
Dividend Yield
1.05%

Growth (CAGR)

Revenue 5Y
11.06%
Profit 5Y
28.33%
Revenue (YoY)
19.10%
Earnings (YoY)
27.80%

Profitability & Returns

ROCE
25.67%
ROE
20.13%
ROA
16.05%
Profit Margin
18.75%
Op Margin
25.46%
Gross Margin
60.20%
EPS (Latest Qtr)
₹10.13
EPS (TTM)
₹32.40

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
3.38
Current Ratio
3.48
Debt
₹198.99 Cr
Total Assets
₹3,146.00 Cr
Current Assets
₹1,566.49 Cr
Working Capital
₹1,115.88 Cr

Ownership

Promoter Holding
54.70%
Chg in Prom Hold
-0.01%
FII / Inst Holding
32.30%
Chg in FII Hold
-0.93%

Financial Snapshot

Enterprise Value
₹30,828.64 Cr
Total Revenue (TTM)
₹2,890.81 Cr
EBITDA
₹789.93 Cr
Free Cash Flow
₹462.23 Cr
Operating Cash Flow
₹635.61 Cr
Shares Outstanding
₹16.72 Cr
Gross Margin
60.20%
Payout Ratio
43.22%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LALPATHLAB Dr. Lal PathLabs Limited NIFTY_SMALLNSEPHARMA 1,843.70 56.90 ₹30,828.64 Cr 1.05% 25.67% 20.13% 11.06% 28.33%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 491.00 Cr541.00 Cr601.00 Cr539.00 Cr545.00 Cr602.00 Cr660.20 Cr596.70 Cr602.60 Cr669.80 Cr-659.80 Cr702.70 Cr797.70 Cr
Cost of Revenue ------221.00 Cr203.70 Cr117.80 Cr224.70 Cr-224.50 Cr135.20 Cr267.50 Cr
Gross Profit ------439.20 Cr393.00 Cr484.80 Cr445.10 Cr-435.30 Cr567.50 Cr530.20 Cr
Operating Expenses 375.00 Cr395.00 Cr424.00 Cr398.00 Cr401.00 Cr432.00 Cr272.00 Cr274.50 Cr274.40 Cr287.40 Cr-298.10 Cr324.70 Cr327.10 Cr
Operating Income 78.00 Cr111.00 Cr142.00 Cr105.00 Cr108.00 Cr135.00 Cr167.20 Cr118.50 Cr210.40 Cr157.70 Cr-137.20 Cr242.80 Cr203.10 Cr
EBITDA 116.00 Cr146.00 Cr178.00 Cr141.00 Cr145.00 Cr170.00 Cr224.40 Cr179.10 Cr194.80 Cr220.40 Cr-173.60 Cr210.80 Cr279.40 Cr
Interest Expense 9.00 Cr8.00 Cr8.00 Cr7.00 Cr7.00 Cr6.00 Cr6.00 Cr5.30 Cr5.00 Cr4.70 Cr-7.20 Cr6.10 Cr6.30 Cr
Pretax Income 83.00 Cr118.00 Cr152.00 Cr116.00 Cr120.00 Cr150.00 Cr183.10 Cr138.30 Cr153.40 Cr181.10 Cr-124.30 Cr160.10 Cr228.70 Cr
Tax Provision 26.56 Cr34.22 Cr41.04 Cr33.64 Cr33.60 Cr42.00 Cr52.30 Cr40.20 Cr-2.10 Cr47.10 Cr-32.90 Cr27.90 Cr58.20 Cr
Net Income 57.00 Cr84.00 Cr111.00 Cr82.00 Cr86.00 Cr108.00 Cr129.20 Cr96.70 Cr154.80 Cr132.40 Cr-90.50 Cr131.30 Cr169.50 Cr
Diluted EPS 3.404.956.554.875.066.377.74--7.939.015.417.8510.13

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 660.00 Cr791.00 Cr912.00 Cr1,057.00 Cr1,203.00 Cr1,330.00 Cr1,581.00 Cr2,087.40 Cr2,016.64 Cr2,226.50 Cr2,461.22 Cr2,762.76 Cr
Cost of Revenue -------502.30 Cr729.19 Cr764.43 Cr481.46 Cr534.62 Cr
Gross Profit -------1,585.10 Cr1,287.46 Cr1,462.07 Cr1,979.76 Cr2,228.14 Cr
Operating Expenses 504.00 Cr582.00 Cr675.00 Cr793.00 Cr910.00 Cr987.00 Cr1,145.00 Cr848.00 Cr943.58 Cr995.20 Cr1,080.91 Cr1,203.19 Cr
Operating Income 128.00 Cr182.00 Cr210.00 Cr231.00 Cr256.00 Cr271.00 Cr359.00 Cr737.10 Cr343.88 Cr466.87 Cr898.85 Cr1,024.95 Cr
EBITDA 156.00 Cr210.00 Cr238.00 Cr264.00 Cr294.00 Cr344.00 Cr436.00 Cr613.20 Cr531.55 Cr678.41 Cr789.03 Cr853.69 Cr
Interest Expense 001.00 Cr1.00 Cr1.00 Cr15.00 Cr16.00 Cr30.20 Cr37.53 Cr29.36 Cr22.30 Cr22.80 Cr
Pretax Income 140.00 Cr201.00 Cr237.00 Cr261.00 Cr301.00 Cr310.00 Cr394.00 Cr474.90 Cr343.83 Cr505.45 Cr624.80 Cr669.09 Cr
Tax Provision 43.40 Cr68.34 Cr80.58 Cr88.74 Cr99.33 Cr83.70 Cr98.50 Cr124.60 Cr102.75 Cr143.16 Cr132.55 Cr159.33 Cr
Net Income 96.00 Cr133.00 Cr156.00 Cr172.00 Cr200.00 Cr228.00 Cr296.00 Cr344.80 Cr238.85 Cr357.74 Cr487.14 Cr504.78 Cr
Diluted EPS 8.757.999.3110.2411.9513.5517.4920.7914.3721.4929.2030.20

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 475.00 Cr625.00 Cr690.00 Cr916.00 Cr1,091.00 Cr1,374.00 Cr1,661.00 Cr-2,385.56 Cr2,455.96 Cr2,716.79 Cr3,146.00 Cr
Current Assets --------973.09 Cr1,126.70 Cr1,363.51 Cr1,566.49 Cr
Cash & Equivalents --------263.73 Cr360.93 Cr292.63 Cr242.80 Cr
Inventory --------33.81 Cr37.31 Cr36.13 Cr43.85 Cr
Receivables --------70.82 Cr77.40 Cr88.12 Cr110.69 Cr
Total Liabilities --------686.02 Cr570.60 Cr510.31 Cr604.71 Cr
Current Liabilities --------469.75 Cr463.58 Cr402.35 Cr450.62 Cr
Long Term Debt -------166.67 Cr83.33 Cr0--
Total Debt 27.00 Cr00000150.00 Cr-419.50 Cr246.93 Cr157.43 Cr198.99 Cr
Total Equity 315.00 Cr508.00 Cr595.00 Cr788.00 Cr945.00 Cr1,032.00 Cr1,245.00 Cr-1,666.30 Cr1,849.28 Cr2,172.72 Cr2,508.14 Cr
Shares Outstanding --------16.67 Cr16.70 Cr16.72 Cr16.76 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 122.00 Cr159.00 Cr171.00 Cr197.00 Cr219.00 Cr284.00 Cr398.00 Cr-456.03 Cr535.33 Cr568.88 Cr635.61 Cr
Investing Cash Flow -113.00 Cr-163.00 Cr-137.00 Cr-172.00 Cr-100.00 Cr-26.00 Cr-212.00 Cr--287.31 Cr-24.27 Cr-303.16 Cr-421.86 Cr
Financing Cash Flow -1.00 Cr0-32.00 Cr13.00 Cr-55.00 Cr-190.00 Cr-139.00 Cr--283.18 Cr-413.86 Cr-334.03 Cr-263.57 Cr
Capital Expenditure -35.00 Cr-44.00 Cr-51.00 Cr-72.00 Cr-42.00 Cr-79.00 Cr-59.00 Cr--44.57 Cr-57.43 Cr-53.87 Cr-173.38 Cr
Free Cash Flow 87.00 Cr115.00 Cr120.00 Cr125.00 Cr177.00 Cr205.00 Cr339.00 Cr-411.46 Cr477.90 Cr515.01 Cr462.23 Cr
Net Change in Cash 8.00 Cr-5.00 Cr2.00 Cr37.00 Cr64.00 Cr67.00 Cr48.00 Cr--114.46 Cr97.20 Cr-68.31 Cr-49.83 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -------75.9%63.8%65.7%80.4%80.6%
Operating Margin % 19.4%23.0%23.0%21.9%21.3%20.4%22.7%35.3%17.1%21.0%36.5%37.1%
Net Margin % 14.5%16.8%17.1%16.3%16.6%17.1%18.7%16.5%11.8%16.1%19.8%18.3%
ROE % 30.5%26.2%26.2%21.8%21.2%22.1%23.8%-14.3%19.3%22.4%20.1%
ROCE % --------17.9%23.4%38.8%38.0%

Shareholding Pattern

Insiders
54.70%
Institutions
32.30%
Public Float
71.30%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LALPATHLAB

Google News Mon, 19 Oct 2026

Dr. Lal PathLabs (NSEI:LALPATHLAB) Stock Forecast & Analyst Predictions - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNeG0zUHBlTl80WE9MbVFFZjZtV3VpMzBXMk1uUWc5WDB4d3J5V3dyeFUxWHlydjYwSWI1b1RMUHVRVTJreWZtLWNUb0V4VjlOczNEMG9jb1JpZ1FyLWhGS0ZrV0NseFo5M3ljWWNqODNYQV9RcjhNRDhRd1NqUHhhaWd5T01sbnZUeUR0MS…

Google News hu, 25 Jun 2026

LALPATHLAB Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5CLXc1aE0tRFhYRTFKYWdNTS1FWnpULVFuVGozNGQwcDFSVEhSSnI2VlhCdDZCUEk0UkNfdGRfTXhwMVhEMDl5eWtTWnY3UHFFNDBVWjFZT3dsOVVjcGJSMmswOFRFamhnaUlySmRwOEpxbzUyYVFBcldIbVVXZw?oc=5" target="_blan…

Google News Fri, 16 Oct 2026

LALPATHLAB Outlook for the Week - Equitypandit

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5kMEhfQTNXcWhRcnJZY0poTlVoQkxKTFdlYmxPUkZYb01iZElGYVRCOXVJQTVSZEZ6dDBnSGZrMTUyS2hwNVRRTEdBaGN6UEZ0NnhWaGRxZjhjc3VLRHRCMFlxMUx5b2RocFlCYXNR?oc=5" target="_blank">LALPATHLAB Outlook …

Google News hu, 15 Oct 2026

LALPATHLAB Share Price Today - Dr. Lal Path Labs on NSE/BSE - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE1lY3NnT21mM2x1cW55OHZpVjd5WHlnM05IQV9zZmp5eW9iOVAwZnk2S3A4RVFEdkhIdHFMV05mZVYxLV9SMWx1elNxUlFmYUVrYmZRUGdzWDcxU0U?oc=5" target="_blank">LALPATHLAB Share Price Today - Dr. Lal Path …

Google News Wed, 30 Sep 2026

Dr. Lal PathLabs Limited acquired 70% stake in Sn Genelab Private Limited. - www.marketscreener.com

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSWoxelZpcUcwdUtCZmkzNGN2bkpVZWdCTGFFcEJ2Q051M2MtTEVKVm8yYURleDVMRHU0b0lPNnB0RmR0Sno2Nm9NSFMwcXJJSGdoTFVlcFV2eUN0OTFZa01kTHR2OGRtUDVvdnB1ckZJbXZQak9JSUljM3NjUE4yTEM4V3NmN1ZLT1VGcD…

Google News Fri, 19 Dec 2025

Dr Lal PathLabs shares tank 51% today, but here’s why investors shouldn’t panic - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQb2xWU3ZQb1pTM1BTUkdVdkQwb052dGRWZXBXYmktSE9iUWdiMVBrYXhlOWdmZGh1T0dYcFI4TzNjc093RXV5TEFLY2U0UjZiNWdXNTV6VmVNQng3cWRldmVfYTlJNzF1TDluMzFuYzNOZ3JlWUNxdjIzN3VZRVhRTEpKX3NubWNtUWZTU1…

LALPATHLAB — Frequently Asked Questions

What is the current share price of Dr. Lal PathLabs Limited (LALPATHLAB)?

As of 2026-10-24 04:55 IST, Dr. Lal PathLabs Limited (LALPATHLAB) trades at ₹1,843.70 on NSE. Its 52-week range is ₹1,300.98 to ₹2,005.10.

What is the market capitalisation of LALPATHLAB?

Dr. Lal PathLabs Limited (LALPATHLAB) has a market capitalisation of ₹30,828.64 Cr on NSE.

What is the P/E ratio of LALPATHLAB?

LALPATHLAB trades at a trailing price-to-earnings (P/E) ratio of 56.90. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 12.87.

Does LALPATHLAB pay a dividend?

Dr. Lal PathLabs Limited (LALPATHLAB) currently offers a dividend yield of 1.05%.

What is the return on equity (ROE) of LALPATHLAB?

LALPATHLAB has a return on equity (ROE) of 20.13%. Its return on capital employed (ROCE) is 25.67%.

Is LALPATHLAB a good stock to buy?

This page provides a data-driven analysis of Dr. Lal PathLabs Limited (LALPATHLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space